A Multi-center Trial on Efficacy and Safety of the LifeTech CeraFlex ASD Occluder for Transcatheter Closure in Patients with Secundum Atrial Septal Defects

Overview

Journal Cardiovasc Diagn Ther

Publisher AME Publishing Company

Specialty Cardiology & Vascular Diseases

Date 2022 Aug 29

PMID 36033225

Authors

Celina Fritz

Andrea Engelhardt

Jochen Grohmann

Ingo Dahnert

Johanna Hummel

Daniel Tanase

Peter Ewert

Andreas Eicken

Affiliations

Soon will be listed here.

Abstract

Background: The last decades have brought remarkable improvements in treatment strategy and occluder modification of secundum atrial septal defect (ASD) closure. Approval, efficacy and safety of ASD closure devices have previously been demonstrated. This study investigated the clinical efficacy and safety of the LifeTech CeraFlex ASD occluder for interventional closure of secundum ASD with a 6-month follow-up (FU).

Methods: Procedure specific data was collected on patients considered for ASD closure with the CeraFlex occluder between April 2016 and December 2019 in three German centers. Efficacy and safety were assessed after device closure, at discharge, and at 6-month FU.

Results: The primary endpoint (successful ASD closure without severe complications) was reached by 102/103 patients (99%). Device embolization occurred in two patients (one early and one late embolization). After early snare-retrieval of an embolized device, this ASD was closed surgically and in the other patient with late device embolization the defect was closed with a larger CeraFlex occluder. The secondary endpoint (clincal efficacy after 6 months) was reached by 94/98 patients since new onset of arrhythmia occurred in four patients. Three patients had withdrawn their study-participation and one patient had moderate residual shunt, but not related to the occluder. Incomplete right bundle branch block (iRBBB) was seen in 31 patients. At last FU only 17 patients had remaining iRBBB documenting effective volume unloading of the right ventricle.

Conclusions: Catheter interventional closure of secundum ASDs with the CeraFlex ASD occluder was feasible, safe and effective in this study.

Citing Articles

Arrhythmias Following Patent Foramen Ovale Closure: An Unsolved Enigma.

Karanikola A, Soulaidopoulos S, Leontsinis I, Dri E, Sagris M, Kordalis A Life (Basel). 2025; 14(12.

PMID: 39768297 PMC: 11678317. DOI: 10.3390/life14121590.

Pulmonary hypertension in adults with congenital heart defects (ACHDs) in light of the 2022 ESC PAH guidelines-part II: supportive therapy, special situations (pregnancy, contraception, non-cardiac surgery), targeted pharmacotherapy, organ....

Kaemmerer H, Diller G, Dahnert I, Achenbach S, Eichstaedt C, Eicken A Cardiovasc Diagn Ther. 2024; 14(5):921-934.

PMID: 39513142 PMC: 11538840. DOI: 10.21037/cdt-24-167.

Recent Development of Biodegradable Occlusion Devices for Intra-Atrial Shunts.

Li Y, Chen Z, Xie Z, Wang S, Xie Y, Zhang Z Rev Cardiovasc Med. 2024; 25(5):159.

PMID: 39076475 PMC: 11267192. DOI: 10.31083/j.rcm2505159.

Transcatheter Closure of Secundum Atrial Septal Defects in Pediatric Patients: A 15-Year Single-Center Experience.

Dogan E, Levent E Cureus. 2024; 16(3):e57150.

PMID: 38681362 PMC: 11055965. DOI: 10.7759/cureus.57150.

Nanotechnology Innovations in Pediatric Cardiology and Cardiovascular Medicine: A Comprehensive Review.

Moisa S, Burlacu A, Butnariu L, Vasile C, Brinza C, Spoiala E Biomedicines. 2024; 12(1).

PMID: 38255290 PMC: 10813221. DOI: 10.3390/biomedicines12010185.

References

Vincent R, Raviele A, Diehl H . Single-center experience with the HELEX septal occluder for closure of atrial septal defects in children. J Interv Cardiol. 2003; 16(1):79-82. DOI: 10.1046/j.1540-8183.2003.08005.x. View

Cowley C, Lloyd T, Bove E, Gaffney D, Dietrich M, Rocchini A . Comparison of results of closure of secundum atrial septal defect by surgery versus Amplatzer septal occluder. Am J Cardiol. 2001; 88(5):589-91. DOI: 10.1016/s0002-9149(01)01750-7. View

Chen T, Hsiao Y, Cheng C, Mao C, Chen D, Tsai M . In-Hospital and 4-Year Clinical Outcomes Following Transcatheter Versus Surgical Closure for Secundum Atrial Septal Defect in Adults: A National Cohort Propensity Score Analysis. Medicine (Baltimore). 2015; 94(38):e1524. PMC: 4635747. DOI: 10.1097/MD.0000000000001524. View

Moore J, Hegde S, El-Said H, Beekman 3rd R, Benson L, Bergersen L . Transcatheter device closure of atrial septal defects: a safety review. JACC Cardiovasc Interv. 2013; 6(5):433-42. DOI: 10.1016/j.jcin.2013.02.005. View

Haas N, Happel C, Soetemann D, Hanslik A, Moysich A, Kececioglu D . Optimal septum alignment of the Figulla Flex occluder to the atrial septum in patients with secundum atrial septal defects. EuroIntervention. 2014; 11(10):1153-60. DOI: 10.4244/EIJY14M12_09. View

Horer J, Eicken A, Muller S, Schreiber C, Cleuziou J, Prodan Z . Risk factors for prolonged intensive care treatment following atrial septal defect closure in adults. Int J Cardiol. 2007; 125(1):57-61. DOI: 10.1016/j.ijcard.2007.02.022. View

Apostolopoulou S, Tsoutsinos A, Laskari C, Kiaffas M, Rammos S . Large single centre experience with the Cera™ and CeraFlex™ occluders for closure of interatrial communications: usefulness of the flexible rotation feature. Cardiovasc Interv Ther. 2016; 33(1):70-76. DOI: 10.1007/s12928-016-0440-y. View

Crawford D, Naidu S, Shah A, Davila V, Stone W . Endovascular Retrieval of an Embolized Atrial Septal Occluder Device From the Abdominal Aorta. Vasc Endovascular Surg. 2018; 52(8):669-673. DOI: 10.1177/1538574418790393. View

OByrne M, Gillespie M, Kennedy K, Dori Y, Rome J, Glatz A . The influence of deficient retro-aortic rim on technical success and early adverse events following device closure of secundum atrial septal defects: An Analysis of the IMPACT Registry. Catheter Cardiovasc Interv. 2016; 89(1):102-111. PMC: 5115996. DOI: 10.1002/ccd.26585. View

10.

Kenny D, Eicken A, Dahnert I, Boudjemline Y, Sievert H, Schneider M . A randomized, controlled, multi-center trial of the efficacy and safety of the Occlutech Figulla Flex-II Occluder compared to the Amplatzer Septal Occluder for transcatheter closure of secundum atrial septal defects. Catheter Cardiovasc Interv. 2019; 93(2):316-321. DOI: 10.1002/ccd.27899. View

11.

Chessa M, Carminati M, Butera G, Bini R, Drago M, Rosti L . Early and late complications associated with transcatheter occlusion of secundum atrial septal defect. J Am Coll Cardiol. 2002; 39(6):1061-5. DOI: 10.1016/s0735-1097(02)01711-4. View

12.

El-Said H, Hegde S, Foerster S, Hellenbrand W, Kreutzer J, Trucco S . Device therapy for atrial septal defects in a multicenter cohort: acute outcomes and adverse events. Catheter Cardiovasc Interv. 2014; 85(2):227-33. DOI: 10.1002/ccd.25684. View

13.

Warnes C, Williams R, Bashore T, Child J, Connolly H, Dearani J . ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the.... J Am Coll Cardiol. 2008; 52(23):e143-e263. DOI: 10.1016/j.jacc.2008.10.001. View

14.

Bhattacharjya S, Pillai L, Doraiswamy V, Satyanarayana R, Chandrasekaran R, Pavithran S . Prospective concurrent head-to head comparison of three different types of nitinol occluder device for transcatheter closure of secundum atrial septal defects. EuroIntervention. 2019; 15(4):e321-e328. DOI: 10.4244/EIJ-D-18-01016. View

15.

Astarcioglu M, Kalcik M, Sen T, Aykan A, Gokdeniz T, Gursoy O . Ceraflex versus Amplatzer occluder for secundum atrial septal defect closure. Multicenter clinical experience. Herz. 2015; 40 Suppl 2:146-50. DOI: 10.1007/s00059-014-4192-0. View

16.

Amin Z, Hijazi Z, Bass J, Cheatham J, Hellenbrand W, Kleinman C . Erosion of Amplatzer septal occluder device after closure of secundum atrial septal defects: review of registry of complications and recommendations to minimize future risk. Catheter Cardiovasc Interv. 2004; 63(4):496-502. DOI: 10.1002/ccd.20211. View

17.

Jung S, Choi J . Transcatheter closure of atrial septal defect: principles and available devices. J Thorac Dis. 2018; 10(Suppl 24):S2909-S2922. PMC: 6174149. DOI: 10.21037/jtd.2018.02.19. View

18.

Johnson J, Marquardt M, Ackerman M, Asirvatham S, Reeder G, Cabalka A . Electrocardiographic changes and arrhythmias following percutaneous atrial septal defect and patent foramen ovale device closure. Catheter Cardiovasc Interv. 2011; 78(2):254-61. DOI: 10.1002/ccd.23028. View

19.

Masura J, Gavora P, Formanek A, Hijazi Z . Transcatheter closure of secundum atrial septal defects using the new self-centering amplatzer septal occluder: initial human experience. Cathet Cardiovasc Diagn. 1997; 42(4):388-93. DOI: 10.1002/(sici)1097-0304(199712)42:4<388::aid-ccd7>3.0.co;2-7. View

20.

Gungor Kaya M, Akpek M, Celebi A, Saritas T, Meric M, Soylu K . A multicentre, comparative study of Cera septal occluder versus AMPLATZER Septal Occluder in transcatheter closure of secundum atrial septal defects. EuroIntervention. 2014; 10(5):626-31. DOI: 10.4244/EIJY14M07_04. View